TACE联合毒痰瘀脾虚方治疗原发性肝癌患者临床疗效研究

doi:10.3969/j.issn.1672-5069.2022.06.029

摘要/Abstract

摘要： 目的探讨采用肝动脉化疗栓塞术(TACE)联合毒痰瘀脾虚方治疗原发性肝癌(PLC)患者的近期疗效,以及对血清血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(b-FGF)和凝血酶敏感蛋白-1(TSP-1)水平的影响。方法 2020年6月～2022年1月我院收治的68例PLC患者被随机分为对照组34例和观察组34例,分别给予以顺铂、表阿霉素和氟尿嘧啶为主的TACE治疗,观察组在对照组治疗的基础上联合毒痰瘀脾虚方辅助治疗12周。使用流式细胞仪检测外周血淋巴细胞亚群,采用COBAS E601电化学发光分析仪检测血清甲胎蛋白(AFP)、癌胚抗原(CEA)、CA19-9和CA125,采用 ELISA 法检测血清VEGF、b-FGF和TSP-1水平。结果在治疗后3个月末,观察组部分缓解、疾病稳定和疾病进展发生率分别为14.7%、61.7%和23.5%,与对照组的11.7%、52.9%和35.2%比,无显著性差异(P＞0.05);观察组外周血CD3⁺、CD4⁺、NK细胞百分比和CD4⁺/ CD8⁺细胞比值分别为(66.1±5.4)%、(39.8±4.2)%、(14.7±2.8)%和(1.5±0.2),与对照组【分别为(60.2±5.3)%、(35.5±3.4)%、(10.2±2.4)%和(1.4±0.2)】比,无显著性差异(P＞0.05);观察组血清AFP、CEA、CA19-9和CA125水平分别为(284.7±29.4)μg/L、(13.2±3.4)ng/mL、(36.1±10.7)U/mL和(26.4±13.7)U/mL,显著低于对照组【分别为(334.4±27.6)μg/L、(17.7±3.4)ng/mL、(44.6±11.2)U/mL和(35.8±14.4)U/mL,P<0.05】;观察组肝功能指标改善也显著优于对照组(P<0.05);观察组血清VEGF、b-FGF和TSP-1水平分别为(126.3±52.1)pg/mL、(32.1±8.3)pg/mL和(68.3±31.2)μg/mL,均显著低于对照组【分别为(194.3±62.2)pg/mL、(44.7±9.5)pg/mL和(91.9±32.4)μg/mL,P＜0.05】。结论加用毒痰瘀脾虚方辅助TACE治疗PLC患者近期疗效不明显,但可能有助于改善肝功能和肿瘤指标,并可能通过调节血管生成因子水平而抑制肿瘤进展。

关键词: 原发性肝癌, 肝动脉化疗栓塞术, 毒痰瘀脾虚方, 血管内皮生长因子, 碱性成纤维细胞生长因子, 凝血酶敏感蛋白-1, 治疗

Abstract: Objective The aim of this study was to investigate the short-term efficacy of auxiliary DutanyuPixu Formulae, herbal medicine compound, therapy after transcatheter arterial chemoembolization (TACE) in the treatment of patients with primary liver cancer(PLC) and to observe the changes of serum vascular endothelial growth factor (VEGF), basic fibroblast growth factor (b-FGF) and thrombospondin-1 (TSP-1) levels. Methods 68 patients with PLC were encountered in our hospital between June 2020 and January 2022, and were randomly divided into control and observation group, with 34 cases in each group. The patients in the control group was treated with TACE, with cisplatin, epirubicin and fluorouracil infusion, and those in the observation group was treated with DutanyuPixu Formulae after TACE. The percentages of peripheral blood lymphocyte subsets were detected by FCM, serum AFP, CEA, CA19-9 and CA125 were assayed. Serum VEGF, b-FGF and TSP-1 levels were detected by ELISA. Results At the end of three month treatment, the partial remission, stable disease and disease progression rates in the observation group were 14.7%, 61.7% and 23.5%, not significantly different compared to 11.7%, 52.9% and 35.2% in the control(P＞0.05); the percentages of CD3⁺, CD4⁺, NK and ratio of CD4⁺/ CD8⁺ were (66.1±5.4)%,(39.8±4.2)%, (14.7±2.8)% and (1.5±0.2), not significantly different compared to [(60.2±5.3)%, (35.5±3.4)%, (10.2±2.4)% and (1.4±0.2), respectively, P＞0.05]; serum AFP, CEA, CA19-9 and CA125 levels were (284.7±29.4)μg/L, (13.2±3.4)ng/mL, (36.1±10.7)U/mL and (26.4±13.7)U/mL, all significantly lower than [(334.4±27.6)μg/L, (17.7±3.4)ng/mL, (44.6±11.2)U/mL and (35.8±14.4)U/mL, respectively, P<0.05] in the control; the improvement of liver function tests was also superior to that in the control(P<0.05); serum VEGF, b-FGF and TSP-1 levels were (126.3±52.1)pg/mL, (32.1±8.3)pg/mL and (68.3±31.2)μg/mL, all significantly lower than [(194.3±62.2)pg/mL, (44.7±9.5)pg/mL and (91.9±32.4)μg/mL, respectively, P＜0.05] in the control group. Conclusion The auxiliary DutanyuPixu Formulae therapy after TACE in treatment of patients with PLC do not improve the short-term clinical efficacy, but it seems to improve the liver function tests and tumor indicators, which might inhibit the tumor progression by reducing serum angiogenic factor levels.

Key words: Hepatoma, DutanyuPixu Formulae, herbal medicine, Transcatheter arterial chemoembolization, Vascular endothelial growth factor, Basic fibroblast growth factor, Thrombospondin-1, Therapy

毛月琴, 张红侠, 宋海燕, 刘波, 董静, 陈照林, 杨小康, 周旭, 娄方明. TACE联合毒痰瘀脾虚方治疗原发性肝癌患者临床疗效研究[J]. 实用肝脏病杂志, 2022, 25(6): 873-876.

Mao Yueqin, Zhang Hongxia, Song Haiyan, et al.. Clinical efficacy of auxiliary DutanyuPixu Formulae therapy after TACE in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2022, 25(6): 873-876.

参考文献

[1] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2021, 7(1): 6.
[2] Makary MS, Khandpur U, Cloyd JM, et al. Local regional therapy approaches for hepatocellular carcinoma: recent advances and management strategies. Cancers (Basel), 2020, 12(7): 1914.
[3] Bai XM, Cui M, Yang W, et al. The 10-yearsurvival analysis of radiofrequency ablation for solitary hepatocellular carcinoma 5 cm or smaller: primary versus recurrent HCC. Radiology, 2021, 300(2): 458-469.
[4] PiñeiroFernández J, Luddy KA, Harmon C, et al. Hepatictumor microenvironments and effects on NK cell phenotype and function. Int J MolSci, 2019, 20(17): 4131.
[5] Yang YM, Kim SY, Seki E. Inflammation andliver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis, 2019, 39(1): 26-42.
[6] Shiraha H, Iwamuro M, Okada H. Hepaticstellate cells in liver tumor. Adv Exp Med Biol, 2020, 1234: 43-56.
[7] Yuan P, Zhang Z, Kuai J. Analysis on efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma. J BUON, 2019, 24(1): 163-170.
[8] Xu K, Wang ZX, et al. VEGF family gene expression as prognostic biomarkers for Alzheimer's disease and primary liver cancer. Comput Math Methods Med, 2021,2021:3422393.
[9] Joo YY, Jang JW, Lee SW, et al.Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression. Sci Rep, 2019, 9(1): 9137.
[10] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版). 中华肝脏病杂志, 2022, 30(4): 367-388.
[11] Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev, 2019, 72: 28-36.
[12] 石元凯,孙燕.临床肿瘤内科手册.第6版,北京:人民卫生出版社,2014,30-34.
[13] Zhang X, Wu Z, Peng Y, et al. Correlationship between Ki67, VEGF, and p53 and hepatocellular carcinoma recurrence in liver transplant patients. Biomed Res Int, 2021, 2021: 6651397.
[14] Bhoori S, Mazzaferro V. Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward. Lancet Oncol, 2020, 21(6): 740-741.
[15] El Shorbagy S, abuTaleb F, Labib HA, et al. Prognostic significance of VEGF and HIF-1 α in hepatocellular carcinoma patients receiving sorafenib versus metformin sorafenib combination. J Gastrointest Cancer, 2021, 52(1): 269-279.
[16] 刘瑞清. 缺氧诱导因子-1α参与肝纤维化形成机制研究进展. 实用肝脏病杂志, 2021, 24(1): 145-148.
[17] Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma.Clin Cancer Res, 2019, 25(3): 912-920.
[18] Uzzaman A, Zhang X, Qiao Z, et al. Discovery of small extracellular vesicle proteins from human serum for liver cirrhosis and liver cancer. Biochimie, 2020, 177: 132-141.
[19] Yang HD, Kim HS, Kim SY, et al. HDAC6 suppresses Let-7i-5p to elicit TSP1/CD47-mediated anti-tumorigenesis and phagocytosis of hepatocellular carcinoma. Hepatology, 2019, 70(4): 1262-1279.
[20] Li Y, Turpin CP, Wang S. Role of thrombospondin 1 in liver diseases. Hepatol Res, 2017, 47(2): 186-193.